270 related articles for article (PubMed ID: 28754096)
1. Successful treatment with anti-programmed-death-1 antibody in a relapsed natural killer/T-cell lymphoma patient with multi-line resistance: a case report.
Lai J; Xu P; Jiang X; Zhou S; Liu A
BMC Cancer; 2017 Jul; 17(1):507. PubMed ID: 28754096
[TBL] [Abstract][Full Text] [Related]
2. Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma.
Li X; Cheng Y; Zhang M; Yan J; Li L; Fu X; Zhang X; Chang Y; Sun Z; Yu H; Zhang L; Wang X; Wu J; Li Z; Nan F; Tian L; Li W; Young KH
J Hematol Oncol; 2018 Jan; 11(1):15. PubMed ID: 29386072
[TBL] [Abstract][Full Text] [Related]
3. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase.
Kwong YL; Chan TSY; Tan D; Kim SJ; Poon LM; Mow B; Khong PL; Loong F; Au-Yeung R; Iqbal J; Phipps C; Tse E
Blood; 2017 Apr; 129(17):2437-2442. PubMed ID: 28188133
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma.
Bi XW; Wang H; Zhang WW; Wang JH; Liu WJ; Xia ZJ; Huang HQ; Jiang WQ; Zhang YJ; Wang L
J Hematol Oncol; 2016 Oct; 9(1):109. PubMed ID: 27737703
[TBL] [Abstract][Full Text] [Related]
5. Chemorefractory extranodal nasal-type natural-killer/T-cell lymphoma with great response to pembrolizumab in a young patient: a case report.
Adabifirouzjaei F; Khazai B; Azami G; Shoja-E-Razavi G
J Med Case Rep; 2021 Oct; 15(1):539. PubMed ID: 34702349
[TBL] [Abstract][Full Text] [Related]
6. Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase.
Wang L; Wang H; Wang JH; Xia ZJ; Lu Y; Huang HQ; Jiang WQ; Zhang YJ
Oncotarget; 2015 Oct; 6(30):30317-26. PubMed ID: 26210287
[TBL] [Abstract][Full Text] [Related]
7. Significance of circulating Epstein-Barr virus DNA monitoring after remission in patients with extranodal natural killer T cell lymphoma.
Cho J; Kim SJ; Park S; Yoo KH; Ki CS; Ko Y; Kim WS
Ann Hematol; 2018 Aug; 97(8):1427-1436. PubMed ID: 29627879
[TBL] [Abstract][Full Text] [Related]
8. Sustained remission of multi-line relapsed extranodal NK/T-cell lymphoma, nasal type, following sintilimab and chidamide: A case report.
Xu J; Xu X; Chen J; Wang J; Jiang C; Lv C; Chen B
Medicine (Baltimore); 2021 Mar; 100(10):e24824. PubMed ID: 33725836
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus‒Positive and ‒Negative Relapsed or Refractory Non-Hodgkin Lymphomas.
Kim SJ; Hyeon J; Cho I; Ko YH; Kim WS
Cancer Res Treat; 2019 Apr; 51(2):611-622. PubMed ID: 30025443
[TBL] [Abstract][Full Text] [Related]
10. Series of extranodal natural killer/T-cell lymphoma, nasal type, with periorbital involvement.
Termote K; Dierickx D; Verhoef G; Jorissen M; Tousseyn T; Mombaerts I
Orbit; 2014 Aug; 33(4):245-51. PubMed ID: 24831171
[TBL] [Abstract][Full Text] [Related]
11. Updating targets for natural killer/T-cell lymphoma immunotherapy.
Xue W; Zhang M
Cancer Biol Med; 2021 Feb; 18(1):52-62. PubMed ID: 33628584
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of PD-1 inhibitor alone or combined with chemotherapy in patients with relapsed or refractory extranodal natural Killer/T cell lymphoma: A retrospective study.
Tian J; Hao M; Liu Q; Xiao F; Li Y; Qi M; Gao J; Liu L; Yin D
Hematol Oncol; 2023 Aug; 41(3):396-406. PubMed ID: 36516297
[TBL] [Abstract][Full Text] [Related]
13. Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study.
Huang H; Zhu J; Yao M; Kim TM; Yoon DH; Cho SG; Eom HS; Lim ST; Yeh SP; Song Y; Kwong YL; Kim JS; Jin J; Shi Y; Kim H; Qing M; Zhou T; Gao G; Dong Z; Qi M; Kim WS
J Hematol Oncol; 2021 Feb; 14(1):25. PubMed ID: 33588922
[TBL] [Abstract][Full Text] [Related]
14. Serum survivin and vascular endothelial growth factor in extranodal NK/T-cell lymphoma, nasal type: implications for a potential new prognostic indicator.
Kim SJ; Hong M; Do IG; Lee SH; Ryu KJ; Yoo HY; Hong JY; Ko YH; Kim WS
Haematologica; 2015 Mar; 100(3):e106-9. PubMed ID: 25480498
[No Abstract] [Full Text] [Related]
15. Clinical implications of plasma Epstein-Barr virus DNA in early-stage extranodal nasal-type NK/T-cell lymphoma patients receiving primary radiotherapy.
Wang ZY; Liu QF; Wang H; Jin J; Wang WH; Wang SL; Song YW; Liu YP; Fang H; Ren H; Wu RY; Chen B; Zhang XM; Lu NN; Zhou LQ; Li YX
Blood; 2012 Sep; 120(10):2003-10. PubMed ID: 22826562
[TBL] [Abstract][Full Text] [Related]
16. Extranodal lymphomas of head and neck with emphasis on NK/T-cell lymphoma, nasal type.
Coha B; Vucinic I; Mahovne I; Vukovic-Arar Z
J Craniomaxillofac Surg; 2014 Mar; 42(2):149-52. PubMed ID: 23688595
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus-positive nodal T/NK-cell lymphoma: an analysis of 15 cases with distinct clinicopathological features.
Jeon YK; Kim JH; Sung JY; Han JH; Ko YH;
Hum Pathol; 2015 Jul; 46(7):981-90. PubMed ID: 25907865
[TBL] [Abstract][Full Text] [Related]
18. Genomic and transcriptomic landscapes of Epstein-Barr virus in extranodal natural killer T-cell lymphoma.
Peng RJ; Han BW; Cai QQ; Zuo XY; Xia T; Chen JR; Feng LN; Lim JQ; Chen SW; Zeng MS; Guo YM; Li B; Xia XJ; Xia Y; Laurensia Y; Chia BKH; Huang HQ; Young KH; Lim ST; Ong CK; Zeng YX; Bei JX
Leukemia; 2019 Jun; 33(6):1451-1462. PubMed ID: 30546078
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the humoral immune response to the EBV proteome in extranodal NK/T-cell lymphoma.
Liu Z; Sarathkumara YD; Chan JKC; Kwong YL; Lam TH; Ip DKM; Chiu BC; Xu J; Su YC; Proietti C; Cooper MM; Yu KJ; Bassig B; Liang R; Hu W; Ji BT; Coghill AE; Pfeiffer RM; Hildesheim A; Rothman N; Doolan DL; Lan Q
Sci Rep; 2021 Dec; 11(1):23664. PubMed ID: 34880297
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment EBV-DNA copy number is predictive of response and toxicities to SMILE chemotherapy for extranodal NK/T-cell lymphoma, nasal type.
Ito Y; Kimura H; Maeda Y; Hashimoto C; Ishida F; Izutsu K; Fukushima N; Isobe Y; Takizawa J; Hasegawa Y; Kobayashi H; Okamura S; Kobayashi H; Yamaguchi M; Suzumiya J; Hyo R; Nakamura S; Kawa K; Oshimi K; Suzuki R
Clin Cancer Res; 2012 Aug; 18(15):4183-90. PubMed ID: 22675173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
